Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
March 25, 2024 06:00 ET
|
Verge Genomics
SOUTH SAN FRANCISCO, Calif. and BARCELONA, Spain, March 25, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a leading clinical-stage biotechnology company, and Ferrer, an international B Corp...
Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference
February 21, 2024 07:00 ET
|
Verge Genomics
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI)...
Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635
January 09, 2024 07:30 ET
|
Verge Genomics
VRG50635, a small molecule PIKfyve inhibitor, is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform Verge’s proof-of-concept study...
Verge Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
January 03, 2024 07:00 ET
|
Verge Genomics
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI)...
Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635
November 29, 2023 07:00 ET
|
Verge Genomics
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data,...
Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration
October 31, 2023 07:00 ET
|
Verge Genomics
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today...
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases
September 08, 2023 07:00 ET
|
Verge Genomics
Verge to receive up to $42M in upfront and near-term payments, with future cumulative milestones worth up to $840M The collaboration is the second with a leading global pharmaceutical company and...